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Most cancer patients with solid tumors who succumb to their illness die of metastatic disease. While early
detection and improved treatment have led to reduced mortality, even for those with metastatic cancer, some
patients still respond poorly to treatment. Understanding the mechanisms of metastasis is important to improve
prognostication, to stratify patients for treatment, and to identify new targets for therapy. We have shown
previously that expression of nephronectin (NPNT) is correlated with metastatic propensity in breast cancer cell
lines. In the present study, we provide a comprehensive analysis of the expression pattern and distribution of
NPNT in breast cancer tissue from 842 patients by immunohistochemical staining of tissue microarrays from a
historic cohort. Several patterns of NPNT staining were observed. An association between granular cytoplasmic2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.
is is an open access article under the CC BY-NC-ND license (http://
eativecommons.org/licenses/by-nc-nd/4.0/).
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388 Nephronectin in Breast Cancer Steigedal et al. Neoplasia Vol. 20, No. 4, 2018staining (in b10% of tumor cells) and poor prognosis was found. We suggest that granular cytoplasmic staining
may represent NPNT-positive exosomes. We found that NPNT promotes adhesion and anchorage-independent
growth via its integrin-binding and enhancer motifs and that enforced expression in breast tumor cells promotes
their colonization of the lungs. We propose that NPNT may be a novel prognostic marker in a subgroup of breast
cancer patients.
Neoplasia (2018) 20, 387–400G
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etastasis is themajor cause of death for patients with solid tumors who
ccumb to their disease [1]. Breast cancer metastases usually develop in
ultiple organs including lymph nodes, bone, lung, liver, and brain [2].
nderstanding the molecular mechanisms by which breast tumors
etastasize is integral to improving outcome for patients with advanced
sease. However, the metastatic process and the selective preference of
mor cells for certain tissues is complex and dependent on various
ctors including vascular patterns, adhesion factors, and tumor cell
teractions with the stroma at the metastatic site [3].
Human breast cancer is heterogeneous and is divided into
bgroups that vary in gene expression profiles, phenotype,
gressiveness, metastatic propensity, and response to treatment
–6]. A comprehensive effort with screening programs, development
new chemotherapeutic and endocrine regimens, and implemen-
tion of targeted agents has contributed to reduced breast cancer
ortality [4]. Stratification of patients into optimal treatment
gimens is therefore of increasing importance. The four original
olecular subtypes of breast cancer (Luminal, HER2-enriched,
sal-like, and normal-like) [5,6] have subsequently been divided into
ditional subtypes that are likely to be of clinical relevance [4,7].
Nephronectin (NPNT), also known as POEM (Preosteoblast
pidermal Growth Factor (EGF)-like repeat protein with MAM
main,) was initially identified as a gene involved in embryonic
velopment of endocrine organs via interactions with the integrin α8β1
ceptor [8–10]. Structurally,NPNThas five EGF-like domains, aMAM
eprin, A5 protein and receptor protein tyrosine phosphatase) domain,
d an RGD (Arg-Gly-Asp) integrin-binding motif and is generally
oposed to be a secreted glycoprotein [8,10]. It is secreted by bulge stem
lls in hair follicles and induces differentiation of arrector pili muscle cells
1,12]. NPNT also functions in differentiation of atrioventricular cells
d in promotion of vascularization [13,14].
Few reports exist about the role of NPNT in tumor progression
d metastasis. In a previous study of genes involved in metastatic
ocesses, we analyzed primary tumors of mouse mammary tumor
es exhibiting various degrees of metastatic capacity and found a
rrelation between increased Npnt expression levels and metastatic
opensity [15]. We went on to show that knockdown of NPNT in
e highly metastatic 4T1.2 mammary tumor caused a significant
duction of metastasis to lung, spine, and kidney [15]. In addition,
orowsky et al. reported higher levels of NPNT in metastatic
ammary tumor cells compared to nonmetastatic cells in a different
ngeneic mouse model of breast cancer, supporting a putative role of
PNT as a metastasis-promoting factor [16].
This study reports the first large-scale analysis of NPNT protein
pression in human breast cancer. By immunohistochemistry
HC), we found several different staining patterns for NPNT.ranular cytoplasmic staining was associated with poor prognosis and
ay be consistent with tumor cell–derived extracellular vesicles.
sing preclinical models, we show the necessity of the NPNT
tegrin-binding site in the metastatic process. Our functional data
monstrate that the disruption of the integrin-binding site within
PNT can modulate the propensity of metastatic breast cancer cells
adhere to and colonize the lung. Collectively, our data identify a
nctional role for NPNT during metastasis and describe its
pression and possible prognostic role in a large cohort of breast
ncer patients.
aterials and Methods
atients
The study population has been described previously in detail [17].
riefly, of a total of 1393 new cases of breast cancer occurring
tween 1961 and 2008, 909 cases were available for subtyping using
C and in situ hybridization (ISH) markers as surrogates for gene
pression analyses, and 886 of these were assembled in tissue
icroarrays (TMAs). Patients were followed until death from breast
ncer or from other causes, as registered by the Cause of Death
egistry, or until December 31, 2010. Only cases in TMAs were
cluded in the present study, and 842 cases were suitable for analysis.
wo subtypes, 5 negative phenotype and basal-like phenotype
scribed in Engstrom et al., were merged into triple negative in the
rrent analysis [17]. The study was performed in accordance with
e approval granted by the Regional Committee for Medical and
ealth Research Ethics (REK Midt-Norge, ref. no.:836/2009), and
spensation from the requirement of patient consent was granted.
munostaining (IHC and IF)
The patient samples were fixed in formalin, but details of the
eanalytical conditions are unknown as these samples were collected
er several decades. From TMAs, 4-μm–thick sections were cut and
ounted on Superfrost+ glass slides, dried overnight at 37°C, and
ored in the freezer at −20°C. Before IHC, slides were heated for 2
urs at 60°C and pretreated in a PT Link Pre-Treatment Module for
issue Specimens (Dako Denmark A/S, 2600 Glostrup, DK) with
ffer (High pH Target Retrieval Solution K8004) for 20 minutes at
°C. Immunostaining for NPNT (Atlas Antibodies/Sigma Cat.:
PA003711, Lot No.: D97165, dilution 1:100) was done in a
akoCytomationAutostainer Plus (Dako) at 4°C overnight. Dako
EAL EnVision Detection System with Peroxidase/DAB+, Rabbit/
ouse, code K5007, was used for visualization. The following
ntrols were used: a negative control (omitting the primary
tibody), rabbit IgG isotype control, and a positive control (normal
dney). Sections from validation and optimization of the anti-NPNT
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Neoplasia Vol. 20, No. 4, 2018 Nephronectin in Breast Cancer Steigedal et al. 389tibody (Atlas Antibodies/Sigma) on human tissues are shown in
pplementary Figure S1. The figure shows that the optimal dilution
the antibody was 1:100 in the human samples.
All mouse tissues subjected to immunostaining analyses were fixed in
% buffered formalin for about 24 hours and embedded in paraffin
llowing standard procedures. Tissue blocks were sectioned at 4 μm and
hydrated through Neo-clear and ethanol series. Antigen retrieval was
rformed in 10 mM EDTA (pH 9) by 15-minute boiling in a
icrowave oven. Primary antibodies; anti-human NPNT (Atlas
ntibodies/Sigma, Cat.: HPA003711, Lot No.: D97165, dilution
150), anti-mouse NPNT (Abnova, Cat.: PAB8467, Lot No.: TG
0309, dilution 1:150), anti-V5 (CST, Cat.: 13202S, Lot No.: 2,
lution 1:150), anti-collagen V (Abcam, Cat.: ab7046, Lot No.:
R222605-7, dilution 1:200), anti-Fibronectin (Abcam, Cat.: ab2413,
t No.: GR250744-3, dilution 1:200), and Rabbit IgG Isotype control
D Biosciences, Cat.: 610822, Lot No.: 7069938). All antibodies were
cubated at 4°C overnight. Secondary antibodies were used according to
anufacturer’s recommendations (DakoEnVision,Glostrup,Denmark).
detection was performed using anti-CHMP4B (Atlas Antibodies/
gma, Cat.: HPA051751, Lot No.: R67106, dilution 1:300, anti-V5
ST, Cat.: 13202S, Lot No.: 2, dilution 1:150) and secondary
tibodies; Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed
condary Antibody, Alexa Fluor Plus 647, (Thermo Fisher Scientific,
at.: A32728, Lot No.: RJ243424, dilution 1:1000) and Goat
ti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody,
lexa Fluor Plus 488 (Thermo Fisher Scientific, Cat.: A32731, Lot No.:
J243417, dilution 1:1000). Validation of specificity of the anti-human
PNT (Atlas Antibodies/Sigma and anti-mouse NPNT (Abnova)
tibodies on MMTV-PyMT mouse tissues is shown in Supplementary
gure S2.
oring, Reporting, andClassification of theHumanPatient Samples
All TMA slides were digitized for review as described previously
ter both hematoxylin-eosin-saffron (HES) and IHC staining [17].
ach case was assessed by two researchers independently (by T.S.S.
d A.M.B. or M.V.), one of whom (A.M.B. and M.V.) was a
thologist. Discrepant results were discussed, and consensus was
ached. For diffuse cytoplasmic staining, a staining index was
lculated by multiplying staining intensity by the proportion of
ained cells. Staining intensity was recorded as follows: 0 (no
aining), 1 (weak), 2 (moderate), and 3 (strong). The proportion of
ained cells was scored as 0 (b1%), 1 (1-b10%), 2 (≥10-b50%), and
(≥50%). A staining index of 0-2 was interpreted as negative; 3-9, as
sitive. For granular cytoplasmic staining, any staining was
terpreted as positive, and the proportion of stained cells was
corded as b1%, 1-b10%, ≥10-b50%, and ≥50%. The presence of
attered, strongly cytoplasmic stained tumor cells was recorded.
uclear staining in ≥1% of tumor cells was interpreted as positive.
MTV-PyMT Transgenic Animals
Breast tumor tissues and lungs from MMTV-PyMT animals (The
ckson Laboratory, ME, USA) were collected to represent different
mor stages and used for IHC and ISH analysis, in addition to
olation of primary cells. IHC-stained samples were assessed (by
.S.S. and J.T.) using the same scoring system as for the human
mples. Mice were housed Comparative Medicine Core Facility at
TNU, and the studies were approved by The Norwegian Food
fety Authority (FOTS number 3683) and conducted in accordance
ith the institutional animal ethics guidelines.ell Culture
The mouse cell lines 67NR, 168FARN, 66cl4, 4TO7, and 4T1
ere kindly provided by Dr. Fred Miller (Wayne State University,
etroit, MI) and have been described previously [18]. These cells,
d the 4T1-shNPNT cells, were cultured in DMEM (Gibco,
vitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum
CS , B o v o g e n , V IC , A u s t r a l i a ) a n d 1% ( v / v )
nicillin-streptomycin. 66cl4-cells with stable expression of
Cherry were made as described previously [19] and cultured in
-MEM c o n t a i n i n g 5 - 1 0% FCS a n d 1% ( v / v )
nicillin-streptomycin. Cell lines are routinely tested for mycoplas-
a infection. In addition, a comprehensive screening for viral and
cterial pathogenic contamination was performed at Laboratorio
ynamimed, Madrid, prior to the animal experiments. Additional
formation about the 66cl4-NPNT and 4T1-shNPNT is described
supplementary material.
umor Growth and In Vivo Lung Colonization Assay
Female BALB/c mice (6-8 weeks old, Walter and Eliza Hall Institute,
elbourne, Australia, or from Taconic M&B, Skensved, Denmark) were
esthetized and injected either orthotopically into the mammary gland
×105 cells) or intravenously into the tail vein (5×105 cells) with various
Cherry-expressing 66cl4-cell line variants as described previously [15].
ice bearing mammary tumors were culled after 35 days. Relative tumor
rden (RTB) was measured based on the level of genomic DNA for
Cherry compared to that of vimentin [20]. Primary tumors were
llected and subjected to IHC analyses. Following intravenous injection,
ice were monitored daily and sacrificed after 3 weeks. Lungs were
llected and subjected to RTB, IHC, and IF analyses. Representative left
ng lobes from the lung colonization assay were imaged using the EVOS
Auto Cell Imaging System. Each image was created using a stitch of
veral images to cover the entire lung lobe.Mice were housed either in the
ter MacCallum Animal Care Facility or in the Comparative Medicine
ore Facility at NTNU, and all animal studies were approved by either the
ter MacCallum Animal Ethics Committee (AEEC project number
411) or The Norwegian Food Safety Authority (FOTS number 4551)
d conducted in accordancewith the institutional animal ethics guidelines.
olation of Epithelial Cells
Primary epithelial cells were isolated from FVB wild-type and
MTV-PyMT transgenic mice [21]. Normal and tumor mammary
sues were minced in 5 ml DMEM/F12 (Gibco) with 2% FCS
nvitrogen), 10 mMHEPES, 10 ng/ml epidermal growth factor, 10 μg/
l insulin, 10 mg/ml BSA, 2 mM glutamine, 50 U/ml penicillin, 50 μg/
l streptomycin sulfate, and 1.5mg/ml collagenase type IA-S (Sigma) for
hours at 37°C with gentle rotation. Cells were spun at 1600 rpm for 4
inutes and resuspended in trypsin prior to a second spin at 1400 rpm
d resuspension in fresh medium without collagenase. Cells were
cubated at 37°C with 5% CO2 for about 2-3 weeks.uantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated using the RNeasy kit (Qiagen,
ermantown, MD) and cDNA synthesized using the First-Strand
NA Synthesis Kit (Promega, Madison, WI). qRT-PCRs were
rformed using Bio-Rad SYBR Green Supermix (Bio-Rad, Hercules,
A) according to the manufacturer’s instructions and analyzed using
io-Rad Software. NPNT expression was normalized to Cdc40 and
snk2a2 (geNormPLUS, Southampton, United Kingdom).
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Table 1. Patient and Tumor Characteristics, and Risk of Death from Breast Cancer According to NPNT Positive Staining Pattern
Patient and Tumor Characteristics NPNT Phenotype Positive Cases All Cases d
Nuclear
Staining a
Diffuse Cytoplasmic
Staining b
Single Cells
Positive
Granular Cytoplasmic
Staining c
Granular Cytoplasmic
Staining b10%
Granular Cytoplasmic
Staining ≥10%
Number of cases (%) 385 (45.7) 424 (50.4) 129 (15.3) 116 (13.8) 60 (7.1) 56 (6.7) 842
Mean age at diagnosis (SD) 73.0 (9.7) 72.6 (9.8) 71.3 (10.4) 72.8 (9.3) 72.3 (9.2) 73.3 (9.4) 72.0 (10.4)
Stage at diagnosis (%, 95% CI)
I 180 (44, 39-49) 200 (49, 44-54) 74 (18, 14-22) 62 (15, 12-19) 29 (7, 5-10) 33 (8, 5-11) 411 (49)
II 158 (47,42-53) 178 (53, 48-59) 42 (13, 9-16) 41 (12, 9-16) 23 (7, 4-10) 18 (5, 3-8) 333 (40)
III 26 (51, 37-65) 21 (41, 28-55) 6 (12, 3-21) 7 (14, 4-23) 5 (10, 2-18) 2 (4, 0-9) 51 (6)
IV 20 (49, 33-64) 24 (59, 43-74) 7 (17, 5-29) 6 (15, 4-26) 3 (7, 0-15) 3 (7, 0-15) 41 (5)
Lymph node status at diagnosis (%, 95% CI)
Positive 141 (47, 42-53) 152 (51, 45-57) 39 (13, 9-17) 35 (12, 8-15) 22 (7, 4-10) 13 (4, 2-7) 297 (35)
Negative 129 (49, 43-55) 139 (53, 47-59) 48 (18, 14-23) 37 (14, 10-18) 13 (5, 2-8) 24 (9, 6-13) 264 (31)
Negative, b5 nodes e 30 (45, 33-58) 31 (47, 35-59) 13 (20, 10-29) 11 (17, 8-26) 7 (11, 3-18) 4 (6, 0-12) 66 (8)
Unknown 85 (40, 33-46) 102 (47, 41-54) 29 (13, 9-18) 33 (15, 11-20) 18 (8, 5-12) 15 (7, 4-10) 215 (26)
Molecular subtype (%, 95% CI)
Luminal A 202 (50, 45-55) 191 (47, 42-52) 43 (11, 8-14) 45 (11, 8-14) 22 (5, 3-8) 23 (6, 3-8) 404 (48)
Luminal B HER2- 93 (41, 35-47) 127 (56, 49-62) 61 (27, 21-33) 36 (16, 11-21) 22 (10, 6-14) 14 (6, 3-9) 227 (27)
Luminal B HER2+ 24 (38, 26-49) 44 (69, 57-80) 13 (20, 10-30) 10 (16, 7-25) 4 (6, 3-12) 6 (9, 2-17) 64 (8)
HER2 type 28 (49, 36-62) 29 (51, 38-64) 4 (7, 0-14) 11 (19, 9-30) 6 (11, 2-19) 5 (9, 1-16) 57 (7)
Five negative 12 (40, 22-58) 14 (47, 28-65) 2 (7, 0-16) 3 (10, 0-21) 2 (7, 0-16) 1 (3, 0-10) 30 (4)
Basal 26 (43, 31-56) 19 (32, 20-44) 6 (10, 2-18) 11 (18, 8-28) 4 (7, 0-13) 7 (12, 3-20) 60 (7)
Number of breast cancer deaths 154 164 50 48 29 19 331
Age-adjusted HR (95% CI) f 1.12 (0.90-1.39) 1.04 (0.84-1.30) 0.98 (0.72-1.32) 1.24 (0.91-1.70) 1.61 (1.10-2.37) 0.92 (0.57-1.47) -
Abbreviations: SD: standard deviation, CI: confidence interval, HR: hazard ratio.
a Negative: b1% positive tumor cells, positive: ≥1% positive tumor cells.
b Negative: staining index 0-2, positive: staining index ≥3.
c b10% and ≥10% granular cytoplasmic staining combined.
d Regardless of NPNT expression.
e Negative, but less than 5 nodes examined.
f Adjusted for age at diagnosis in 5-year categories; reference group is patients with negative staining pattern for the respective phenotype.
390 Nephronectin in Breast Cancer Steigedal et al. Neoplasia Vol. 20, No. 4, 2018ELLigence Adhesion and Migration Assay
The xCELLigence system (ACEA Biosciences Inc, San Diego, CA)
as used for RTCA of adhesion and migration according to previous
ports [22–25]. For adhesion assays E-plates (Cat.: 05469830001)
ere coated with recombinantmouseNPNT (Cat.: 4298-NP-050, R&D
stems,Minneapolis,NE) at 0.4, 2, or 10μg/ml for 4 hours at 37°Cprior
seeding. 66cl4- and 4T1-cell variants were detached from tissue culture
ssels using 0.03% EDTA, spun and washed with serum-free medium,
d seeded at either 20,000 or 40,000 cells/well, respectively, in serum-free
edium. Adhesion was recorded by electrical impedance every 5 minutes
r 24 hours. The arbitrary unit “cell index” is ameasure of impedance, and
e value is dependent on the number of cells, the size and shape of the
lls, and the cell attachment quality. For the RGD peptide blocking
periments, E-plates were coated with 2 μg/ml recombinant mouse
PNT and blocked with 3%BSA for 1 hour at 37°C. The 66cl4-EV cells
ere detachedwith EDTA and seeded in serum-freemedium containing a
rambled control peptide (Cat.: H-3166, H-Gly-Arg-Gly-Glu-Ser-OH
rifluoroacetate) or an RGD-blocking peptide (Cat.: H-1346,
-Gly-Arg-Gly-Asp-OH) at 0.5 mg/ml (Bachem, Bubendorf, Switzer-
nd). Adhesion was analyzed at 9 hours after seeding. Migration was
rformed using xCELLigence CIM plates (Cat.: 05665825001)
ntaining 160 μl medium with 10% serum in the lower chamber and
,000 cells (66cl4 cell variants) in serum-free medium in the upper
amber.Wells containing serum-freemedium in the lower chamber were
cluded as controls. Cell index was recorded every 5 minutes.
estern Blot Analysis
Cells were lysed in 10 mM Tris-HCl buffer, and 30 μg of sample was
n on a 10% Bis-Tris gel (Thermo Fisher Scientific, Waltham, MA).
oteins were transferred to PVDF membranes and incubated withti-V5 (CST, Danvers, MA) (1:1000), anti-ALIX (CST, Cat.: 13202S,
ot No.: 2, dilution 1:1000), anti-CHMP4B (Atlas Antibodies/Sigma,
at.: HPA051751, Lot No.: R67106, dilution1:500), and anti-GM130
D Biosciences, Cat.: 610822, Lot No.: 7069938, dilution 1:500).
qual loading was confirmed using anti-GAPDH (Abcam, Cat.: ab9484,
ot No.: GR165366-3, dilution 1:5000), and antibody binding was
tected using HRP-linked secondary antibodies according to manufac-
rer’s instructions (Dako). Full length blots are shown in Supplementary
gure S3.
oft Agar Colony Assay
A bottom layer of 0.75% agarose in α-MEM and a top layer of
36% agarose/α-MEM mixed with 2000 cells/well were added to
ch well in 12-well plates. The cells were fed with normal growth
edium and left for about 2 weeks with 2-3 medium replacements.
lates were stained with 0.005% crystal violet in 2% ethanol/PBS and
lonies counted from triplicate wells per cell line.
inimal Seeding Colony Assay
Cells were seeded onto plastic (10 cells/well in 12-well plates)
d left for 10 days. Medium was replaced twice during the
periment, and the cells were fixed with 6% glutaraldehyde for 30
inutes and stained with 0.1% crystal violet for 30 minutes before
gorous washing with water. Colonies were counted from triplicate
ells/cell line.roliferation Assay
A total of 1.3×106 cells were seeded in 25-cm2 flasks and counted
ter 24, 48, and 72 hours with triplicate measurements per condition.
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Figure 1.Granular NPNT staining patterns are associated with poor outcome in breast cancer patients. Representative images of IHC- and
HES-stained TMA samples showing (A) different staining patterns: no staining, nuclear staining, diffuse cytoplasmic staining, and single
cells positive or granular cytoplasmic staining using antibodies towards human NPNT (Atlas Antibodies/Sigma) imaged at 600×
magnification. The images show representative cases of each staining phenotype, and the cases shown are Luminal A, Luminal A,
Luminal B (HER2−), Luminal A and Luminal B (HER2−), respectively. Scale bars: 50 μm. Survival analysis showing association between
no granular cytoplasmic staining (red line), 1-10% granular positive cells (thick dotted blue line), or N10% granular positive cells (solid
black line) on (B) cumulative risk of death from breast cancer and (C) overall survival for all 842 patients represented in the TMAs.
Neoplasia Vol. 20, No. 4, 2018 Nephronectin in Breast Cancer Steigedal et al. 391NA Scope ISH
ISH for NPNT mRNA was performed on the same mouse
ammary biopsies from the transgenic MMTV-PyMT mice as the
C staining. Custom-made probes (Mm-AF397008) and RNA-
ope®2.0 kit (Advanced Cell Diagnostics, Hayward, CA) were used
cording to the manufacturer’s protocol.
urification and Characterization of Microvesicles and Exosomes
Microvesicles and exosomes were purified using a standardized
quential ultracentrifugation protocol as described by Peinado et al.
6]. Cells were grown in 10% exosome-depleted FCS for 3 days and
e cell culture supernatant harvested by centrifugation at 500g for 10
inutes. The microvesicle fraction (pellet) was collected by spinning at
,000g for 20 minutes. Finally, the exosome fraction was collected by
inning at 100,000g for 70 minutes. Exosomes were washed in 20 ml
S and pelleted again by ultracentrifugation (Beckman 70Ti rotor).
rticle number of isolated microvesicles and exosomes was analyzed
ing the LM10-HS nanoparticle characterization system (NanoSight,
alvern Instruments Ltd, UK).atistical Analyses
We estimated risk of death from breast cancer according to NPNT
pression, calculating cumulative incidence and with death from
her causes as competing events. Risk of death from any cause was
timated using the Kaplan-Meier method. Equality between curves
as assessed using Gray’s test and the log-rank test, respectively. We
ed Cox proportional hazards models to estimate risk of death from
east cancer (censoring at death from other causes) calculating hazard
tios (HRs) with 95% confidence intervals (CIs) and adjusting for
e, stage, grade, and subtype. In vitro experiments were evaluated in
ear regression models. Indicators for each experiment were
cluded to adjust for variation across experiments. In the animal
periments, groups were compared using two-tailed t tests.
esults
We showed previously that NPNT can function as a
ometastatic protein in mouse breast cancer models [15]. With a
ell-characterized set of formalin-fixed and paraffin-embedded
FPE) tumor samples from 842 Norwegian women diagnosed
Figure 2. Phenotypically different patterns of NPNT staining in MMTV-PyMT transgenic mouse tumors. (A) Representative images of IHC-
and HES-stained MMTV-PyMT primary tumors. NPNT was detected using antibodies towards mouse NPNT (Atlas Antibodies/Sigma).
Figure shows antibody-stained sections, IgG Isotype control, control without antibodies (-ab), and HES-stained section from the same
region. (B) Representative images of IHC-stained MMTV-PyMT lung metastases. Arrows indicate no staining (open arrow), diffuse
cytoplasmic staining (filled arrow), and granular staining (triangle). Images are representative of a series of samples from nine mice.
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Figure 3. NPNT is located in granules in 66cl4-NPNT primary tumors. Representative images of IHC-stained 66cl4-EV and 66cl4-NPNT
primary tumors using V5-specific antibodies (Cell Signaling Technology). The left and middle panels show antibody-stained sections,
whereas the right panels show rabbit IgG Isotype staining controls. Granular staining is indicated with open triangles. Images are
representative of a series of samples from five mice.
Neoplasia Vol. 20, No. 4, 2018 Nephronectin in Breast Cancer Steigedal et al. 393ith invasive breast cancer between 1961 and 2008, [17] we assessed
PNT protein expression using IHC on TMAs. Using a standardized
otocol developed for this study, we found positive NPNT staining
596 out of 842 cases (70.8%). Interestingly, although NPNT has
en shown previously to be an extracellular matrix protein, [8–10] in
is study, we identified intracellular staining that we grouped into
ur different patterns: nuclear staining; diffuse positive cytoplasmic
aining; scattered single cells with strong cytoplasmic staining
d granular cytoplasmic staining (Table 1 and Figure 1A). Patients
ith 1-10% granular staining had a poorer prognosis than those
ith no granular staining, evaluating both risk of death from breast
ncer (age-adjusted hazard ratio (HR) 1.61, 95% confidence interval
I) 1.10-2.37, Table 1) and overall survival (Figure 1, B and C). In
ntrast, reduced survival was not found among patients with
gh (≥10%) granular NPNT staining (HR 0.92, 95% CI
57-1.47). In separate analyses of the different molecular subtypes,
e association between the presence of any NPNT granular staining
d prognosis was strongest for the Luminal A subtype (HR 1.70,
% CI 0.99-2.90, P=.054) (Supplementary Table S1). The
maining staining patterns showed no significant association with
ognosis. Adjustment for tumor stage and grade at diagnosis had
tle influence on the estimates. Taken together, this comprehensive
alysis demonstrates for the first time that NPNT is localized
tracellularly in a large number of human breast tumors and that low
vels of intracellular granular staining may be associated with
or prognosis.
To investigate the presence and appearance of NPNT
stribution in mouse breast tumors, we utilized a well-established
ansgenic mouse model of breast cancer, the MMTV-PyMT model
1,27]. NPNT was expressed at higher levels in isolated primary
mor cells compared to normal primary mammary epithelial cells
om wild-type animals (Supplementary Figure S4A), and ISHalyses also confirmed that NPNT is exclusively expressed by the
mor cells (Supplementary Figure S4B). NPNT protein was present
the tumor cells, with phenotypically different patterns including
ffuse cytoplasmic or granular cytoplasmic distribution (Figure 2A).
otein localization was tumor-cell-specific with limited staining in
e extratumoral stromal tissue. Approximately 10% of the tumor
lls had a granular staining pattern of NPNT similar to that found in
e human tumors. The granular NPNT staining pattern has also
en shown to be present in mouse tibias [28]. Direct comparison
tween NPNT and the ECM-proteins Collagen V and Fibronectin
ECM-rich areas of MMTV-PyMT tumors showed some signs of
tracellular presence of NPNT; however, this was not the major site
localization (Supplementary Figure S2B). We investigated NPNT
pression patterns in metastases in lung tissue from the
MTV-PyMT animals and found that the tumor cells were diffusely
sitive in the cytoplasm in the tumor periphery with a few
anular-positive tumor cells similar to that of the primary tumors
igure 2B). Taken together, these findings identify MMTV-PyMT–
iven tumors as a potential model for further studies on the role of
anular NPNT in breast cancer progression and metastasis.
To investigate the in vivo function of NPNT, we expressed a
5-tagged NPNT construct in weakly metastatic mouse 66cl4 breast
ncer cells that express low endogenous levels of NPNT. End-stage
thotopic tumors were then stained by IHC using an anti-V5
tibody. The 66cl4-NPNT primary tumors revealed both diffuse
d granular cytoplasmic NPNT staining similar to the human and
MTV-PyMT tumors (Figure 3). Consistent with our previous
ding that reducing the initially high levels of NPNT in the highly
etastatic cell line 4T1.2 does not affect primary tumor growth [15],
ere were no significant differences in tumor volume or weight at
dpoint between the 66cl4-NPNT and 66cl4-EV tumors (Supple-
entary Figure S5, A and B). Measurement of RTB in spine and
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promote spontaneous metastasis of 66cl4 mammary tumors
upplementary Figure S5, C and D). Taken together, these findings
monstrated that the NPNT staining patterns in the human samples
uld also be observed in the mouse tumors. We suggest that NPNT
ay be more important for metastatic dissemination than primary
mor growth.Transcript levels of NPNT are correlated with the metastatic
opensity of cells in the 4T1 model, with negligible levels in the low
d weakly metastatic 67NR, 168FARN, and 66cl4 cells and higher
vels in the more metastatic 4TO7 and 4T1 cells (Supplementary
igure S6A). Similarly, IHC staining of orthotopic primary tumors
owed some weak cytoplasmic NPNT staining in 67NR tumors and
ightly stronger NPNT staining in patches in 4T1 tumors
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served in these tissue samples. Using 4T1 cells with high
dogenous NPNT levels, we created clones with stable knockdown
NPNT using shRNAs (Supplementary Figure S6C). The
1-shNPNT cell line displayed a significantly reduced ability to
tach to uncoated wells compared to the 4T1-shFF (control) cells,
t adhesion could be rescued by addition of 2 μg/ml recombinant
ouse NPNT (rmNPNT) (Figure 4A). The 4T1-shFF and
1-shNPNT lines both showed a dose-dependent increase in
hesion to rmNPNT-coated plates 1 hour after seeding (Supplemen-
ry Figure S6D).
Previous research has demonstrated that binding of NPNT to its
ceptor integrin α8β1 is mediated through both the high-affinity
GD sequence and an additional downstream enhancer site (EIE)
9,30]. An adhesion assay of 66cl4 cells with enhanced expression of
ther native NPNT or NPNT mutants (RGE or RGE-AIA) showed
at while exogenous NPNT enhanced adhesion, disruption of the
GD-site alone or of both the RGD and the EIE sites significantly
duced adhesion (Figure 4B). Increased NPNT protein expression
as confirmed by Western blot. The 66cl4-EV cells showed a
se-dependent increase in adhesion to plates coated with rmNPNT
igure 4C), and this adhesion was reduced in the presence of a
GD-blocking peptide, demonstrating the involvement of
GD-binding integrins (Figure 4D). There was no impact on either
igration or proliferation upon NPNT overexpression (Figure 4, E
d F). A soft agar colony forming assay showed that the
cl4-NPNT cells exhibited a significantly increased capacity to
ow in an anchorage-independent manner (Figure 4G). This increase
as abolished when both RGD and EIE were mutated. Furthermore,
ing a minimal density seeding assay with 10 cells per well, we
served that cells expressing NPNT had a tendency towards
creased ability to grow colonies from single cells (P=.064) (Figure
). Again, this increase was reduced when both RGD and EIE were
utated. Taken together, these in vitro assays indicate that NPNT is
volved in adhesion and anchorage-independent growth, implying a
le for NPNT in colony formation at the secondary site.
The 66cl4 tumor has low spontaneous metastatic capacity, and we
ve found that expression of NPNT is not sufficient to increase
ontaneous metastasis. However, it is possible that NPNT cangure 4. NPNT increases adhesion and anchorage-independent gr
ELLigence adhesion assay. The figure shows rescue of adhesion i
ouse NPNT (rmNPNT). 4T1-shFF cells express a nontargeting control s
periments (n=4), 1 hour after seeding. (B) xCELLigence adhesion as
GE, or NPNT RGE-AIA mutants in uncoated plates. Data are presented
ur after seeding. Lower panel shows Western blot of cell lysates con
e image is cropped to display only relevant bands, but the full blot
cl4-EV cells in plates coated with rmNPNT at 0.4 μg/ml, 2 μg/ml, or 10
% CI from two experiments (n=4), 1 hour after seeding. (D) Adhesio
ther scrambled peptide or RGD-blocking peptide. Data are presented a
periment. (E) Migration assay in xCELLigence CIM-plates using 66cl4-c
GE-AIA mutants. Migration towards 10% FCS was recorded every 5 m
urs from 5 individual experiments with n=2-4 technical replicates in e
-cm2 flask. Cells were harvested and counted after 24, 48, and 72 h
periments. (G) Soft agar assay for anchorage-independent growth of
o thousand cells/well in 12-well plates were seeded in 0.36% agaro
ata presented as mean ± 95% CI from 3 individual experiments (n=3-9
66cl4-cells expressing EV, NPNT, NPNT RGE, or NPNT RGE-AIA. A t
ngle colonies for 10 days. Graph shows number of colonies as mean
r experiment. # indicates P=.064 when comparing EV-cells with NP
oliferation assay were analyzed with linear regression models. ***Pbfluence the ability of tumor cells to lodge in the lung and grow into
etastatic lesions. To address this, we inoculated mice with tumor
lls via the tail vein and measured subsequent colonization of the
ng. We found that NPNT does promote lung colonization and that
is is mediated via the RGD and EIE sites as shown by both the
creased lung weight and lung tumor burden in mice injected with
lls expressing wild-type NPNT compared to the empty vector (EV)
lls (Figure 5A and B). There was no significant difference between
lls expressing wild-type NPNT and the RGE mutant, but the
creased colonization capability was completely abolished in the
uble mutant, demonstrating the importance of the enhancer EIE
te in the ability to colonize the lung. Images of representative lungs
om each group show that the increased lung weight (Figure 5A) and
lative tumor burden (RTB, Figure 5B) were caused by an increased
mber of metastatic lesions and not just an increase in size of the
lonies (Figure 5C). In summary, this experimental metastasis assay
owed that NPNT promotes lung colonization via the enhancer
IE) sites, possibly aided by the RGD motif, and confirms an in vivo
fect of the two motifs responsible for integrin interaction. IHC
aining of lung metastases from the lung colonization assay showed
at also the tumor cells in the metastatic lesions displayed a granular
ttern of NPNT staining (Figure 5D).
Cancer cell extracellular vesicles and their role in angiogenesis, tumor
ogression, and metastasis is of increasing interest in cancer research
1–33], and NPNT has been detected previously in proteomic
aracterizations of isolated exosomes from human ductal saliva and
lorectal cancer cells [34,35]. The granular staining patterns observed
the human samples, MMTV-PyMT tissues, 66cl4-NPNT primary
mors, and metastases prompted us to speculate that these granular
ructures could be multivesicular bodies containing exosomes. To
dress this, we isolated both exosomes and microvesicles from
cl4-NPNT cells using well-established protocols [26]. ALIX and
HMP4B are commonly used markers for exosome-containing
ultivesicular bodies [35–37]. By Western blot, we show that
PNT co-purified with ALIX and CHMP4B in extracellular vesicles
leased from cells expressing both wild-type and mutant NPNT
igure 6A), hinting that the localization of NPNT tomicrovesicles and
osomes is not integrin-dependent. In accordance with the recom-
ended guidelines for extracellular vesicle characterization [38], weowth. (A) Adhesion of 4T1-shFF and 4T1-shNPNT cells in an
n 4T1-shNPNT cells in plates coated with 2 μg/ml recombinant
hRNA. Data are presented as mean cell index ± 95% CI from two
say of 66cl4-cells expressing either EV or NPNT wild-type, NPNT
as mean cell index ± 95%CI from four experiments (n=3-12), 1
firming NPNT overexpression detected with the anti-V5 antibody.
is shown in Supplementary Figure S3A. (C) Adhesion assay of
μg/ml prior to seeding. Data are presented as mean cell index ±
n assay of 66cl4-EV cells in rmNPNT-coated wells in presence of
smean cell index±SEM from three experiments with n=2 in each
ells expressing either EV or NPNTwild-type, NPNT RGE, or NPNT
inutes, and data are presented as mean cell index ± 95%CI at 12
ach experiment. (F) Cell proliferation assay with 1.3×106 cells per
ours, and data are shown as mean ± SD from three individual
66cl4-cells expressing EV, NPNT, NPNT RGE, or NPNT RGE-AIA.
se/α-MEM medium containing 10% FCS and grown for 10 days.
). (H) Clonogenic cell survival assay with minimal seeding density
otal of 10 cells/well were seeded in 12-well plates and grown as
±95% CI from five individual experiments with n=3-9 replicates
NT-expressing cells. All in vitro data except the qRT-PCR and the
.0001, **Pb.005, *Pb.05.
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396 Nephronectin in Breast Cancer Steigedal et al. Neoplasia Vol. 20, No. 4, 2018ow that the isolated vesicles were negative for the Golgi marker
M130. Immunofluorescence staining of 66cl4-NPNT lung metas-
ses and MMTV-PyMT tumor tissues confirmed colocalization of
PNT with CHMP4B, leading us to propose that the cytoplasmicanular structures could be NPNT-containing multivesicular bodies
igure 6, B and C). In conclusion, we have demonstrated that NPNT
present in extracellular vesicles and thatNPNT facilitates colonization
the metastatic site via its integrin-binding sites.
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e found positive NPNT staining in the majority of patient samples
0.8%), demonstrating that NPNT is present in human breast tumors.
lthough NPNT has been shown by others to be an extracellular matrix
otein, we found that it is also localized intracellularly in tumor cells.
terestingly, in our patients’ tumors, granular intracellular staining in less
an 10%of the cells was associatedwith decreased survival. In addition,we
owed the presence of several phenotypically different intracellular staining
tterns, including diffuse cytoplasmic and nuclear NPNT staining;
wever, neither of these was correlated with survival. This may reflect a
eference of the antibody to recognize the core protein and not the highly
ycosylated secreted forms of the protein when analyzed by IHC.
We did not observe any association between granular NPNT
aining and lymph node metastasis in our patient samples. The total
mber of cases with known metastases was 297. However, lymph
de status was not reported in 215 (25.5%) cases, and the granular
aining pattern was observed in only 116 (13.8%) cases. Our
alyses showed an association between granular staining patterns
10% positive tumor cells) and poor outcome in patients with
minal A subtype (P=.054), but since numbers were lower for the
her subtypes, statistical power was limited in these subgroups.
The nonlinear U-shaped correlation between granular cytoplasmic
aining of NPNT and survival is similar to that shown for various tumor
arkers in glioma [39], prostate [40,41], colorectal [42,43], and
ncreatic cancer [44,45]. In addition, a recent study reported a
-shaped correlation between HER2 protein expression and overall
rvival of breast cancer patients treated with the tyrosine kinase inhibitor
patinib [46]. The explanation for this phenomenon is unclear in most
ses. Similarly, we identified nuclear staining of NPNT in a proportion
the patient samples. This has also been reported in human MCF-7
east cancer cells on the Human Protein Atlas website available from
ww.proteinatlas.org [47]. The possible function of NPNT in the
cleus is unknown and should be followed up in future studies. Taken
gether, this is the first extensive characterization of NPNT expression in
large cohort of breast cancer patients, and although the results need to be
rified by similar studies of other cohorts, they warrant further
vestigation into the role of NPNT in breast cancer.
We have shown previously that reduced NPNT expression in the
ghly metastatic 4T1.2 cells caused a significant reduction in
etastatic tumor burden in lung, spine, and kidneys, [15], and in the
esent study, we show that enhanced expression of NPNT in
w-metastatic 66cl4 cells increased the colonization capacity in the
ngs. Our lung colonization data clearly demonstrated that 66cl4
lls expressing NPNT have a significantly increased capability to seed
d grow in the lungs in an integrin-dependent manner. Our results
e supported by findings from Sánches-Cortés et al. showing that thegure 5.NPNT promotes colonization of the lung via its integrin-binding
PNT RGE-AIA mutants were injected into the lateral tail vein to assess t
ngs were collected after 3 weeks and weighed (mean±SD). **Pb.000
om two separate experiments using 14-15 and 9-10 mice per group.
mplate (n=24-25). Graphs show mean RTB ± SD, ***Pb.0001 when
ngs from each group of mice. Macroscopic view of representative lu
w). The tissues were imaged using the EVOS FL Auto Cell Imag
onochrome CCD camera and visualized using 4× objectives. Each im
tire lung lobe. (D) Representative images of IHC-stained lungs fromm
iddle rows show antibody-stained sections at two different magnifica
ntrols. Scale bars: top and lower row: 100 μm, middle row: 10 μm. T
e representative of a series of samples from five mice.GD and the FEI or EIE sites function synergistically and are both
portant for the interaction between NPNT and its integrin receptor
9]. Previous reports showed that the main receptor for NPNT is
tegrin α8β1 [8,10]. However, we cannot exclude the possibility that
PNT might also interact with other receptors, for example, integrin
Vβ3, on the lung endothelium during the metastatic process [19].
ur findings will prompt further studies on the role of NPNT in breast
ncer using experimental models. The IHC of the MMTV-PyMT
sues revealed staining patterns similar to those in human cancers,
ggesting that this might be a suitable model for further studies.
NPNT has been shown previously to be involved in breast cancer
etastasis in mice [15,16]. Although we were unable to show a link
tween NPNT expression and metastasis in our patient material, the
sults from the experimental models showed that tumor cells
pressing NPNT were more prone to establish colonies in lungs and
display increased adhesion and anchorage-independent growth in
tro in an integrin-dependent manner.
The role of extracellular vesicles in tumor progression and
etastasis is an emerging topic in cancer research, and exosomes
ve been shown to facilitate increased proliferation, evasion of
optosis, stimulation of migration, invasion, and metastasis in
dition to resistance to therapy (reviewed in [48–51]). Furthermore,
e packaging of exosomal content is likely to be specific since the
osomal content influences organotropic dissemination [52]. The
ta presented here suggest for the first time that NPNT may be
calized in mouse breast cancer cell–derived exosomes, and our in
vo data revealed that there might be a link between
PNT-containing exosomes and increased metastatic capacity.
In conclusion, NPNT was originally described as an extracellular
atrix protein [8,10], but the findings from mouse tumor tissues
esented here show intracellular NPNT staining in primary tumors
th diffusely in the cytoplasm and in exosome-containing multi-
sicular bodies. We found that granular intracellular staining in less
an 10 % of tumor cells was associated with decreased survival in a
rge cohort of breast cancer patients and that the integrin-binding
te was important for lung colonization of 66cl4 cells in our animal
odel. There are clearly several mechanisms of action for NPNT in
omoting breast cancer, warranting further investigation into NPNT
a potential prognostic marker and a possible future target for
erapy in a subgroup of breast cancer patients.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.neo.2018.02.008.
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